Research programme: ALC1 protein inhibitors - Eisbach Bio
Alternative Names: Research programme: amplified in liver cancer 1 protein inhibitors - Eisbach Bio; Research programme: CHD1L protein inhibitors - Eisbach BioLatest Information Update: 10 Nov 2023
At a glance
- Originator Eisbach Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action CHD1L protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Nov 2023 Preclinical trials in Cancer in Germany (unspecified route) prior to November 2023 (Eisbach Bio pipeline, November 2023)